WordNet

carcinoma of the liver (同)malignant hepatoma, hepatocarcinoma, hepatocellular_carcinoma

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肝細胞癌に対する治療法の概要 overview of treatment approaches for hepatocellular carcinoma
2. 進行性肝細胞癌に対する全身治療 systemic treatment for advanced hepatocellular carcinoma
3. 肝細胞癌における病期分類および予後因子 staging and prognostic factors in hepatocellular carcinoma
4. 局所性肝細胞癌に対する非外科的治療：動脈塞栓術、放射線療法、および放射線塞栓療法 nonsurgical therapies for localized hepatocellular carcinoma transarterial embolization radiotherapy and radioembolization
5. 肝細胞癌に対する肝移植 liver transplantation for hepatocellular carcinoma

Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice.

Lin WH, Yeh SH, Yang WJ, Yeh KH, Fujiwara T, Nii A, Chang SS, Chen PJ.SourceDepartment of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Mar 15;132(6):1451-62. doi: 10.1002/ijc.27770. Epub 2012 Nov 23.
The telomerase-specific replication-competent oncolytic adenovirus, Telomelysin, was developed for virus-mediated preferential lysis of tumor cells. Its selectivity is derived from a human telomerase reverse transcriptase (hTERT) promoter-driven active viral replication, which occurs in cancer cells
PMID 22886913

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA.SourceDivision of Medical Oncology, Experimental Therapeutics Program, The Pancreas Center at Columbia, New York Presbyterian-Columbia University Medical Center, New York, NY 10032, USA. rlf20@columbia.edu
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.
PURPOSE: We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluor
PMID 23370660